Martin Sim, Senior Scientist at Isomerase Therapeutics Ltd (Cambridge, UK), is taking part as a judge for the upcoming iGEM Grand Jamboree in Paris on 26-28th October. iGEM is an annual synthetic biology event where student teams come together from across the globe to showcase their SynBio projects and compete for the coveted BioBrick trophy. For the first time in 2022, iGEM is being held in Paris, and is occurring as a hybrid event, allowing a greater number of teams than ever before to take part in the Grand Jamboree in-person or virtually.
Martin has previously taken part in iGEM, as an Advisor to the ‘Culture Shock’ team from Newcastle University in 2016. The team’s project, which fused biological parts with electrical components and circuitry to propose and develop a new and emergent field of engineering won a Bronze medal and were nominated for Best Hardware track prizes.
Martin studied at the University of Newcastle where he attained his Masters and PhD in bacterial genetics. Following this Martin entered the biotechnology industry with Enigma Diagnostics (Porton Down, UK) and went on to become a Research Associate within the NUFEB Frontiers in Engineering Biology project at Newcastle University before joining Isomerase in 2017.
Martin commented “I’m extremely thankful that Isomerase is supporting my desire to give back to the iGEM community as a judge at this year’s jamboree. For several years I’ve seen how iGEM can inspire students, bring out the very best teamwork and cultivate the synthetic biologists of the future. The Grand Jamboree is an event like no other and I cannot wait to attend again this year in its new home of Paris!”
Our team is uniquely placed to assist partners with all aspects of microbial product and process discovery and development, including leading-edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, fermentation and process development, DSP, compound isolation, analytical development, and synthetic chemistry. In addition, Isomerase manages other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping and scaled manufacture.
We offer these capabilities underpinned by a portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful product discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
For more information please contact Isomerase via our contact page.